Follow The Filings

RIGL Rigel Pharmaceuticals Inc.

Health Care, filed as RIGEL PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 1 exit

In 2026 Q2 James Silverman sold out of Rigel Pharmaceuticals.

Who owns RIGL

Sorted by value, long equity only, as of 2026 Q2.

History
James Silverman, Opaleye Management exited 2026 Q2 Last 2026 Q1 0.25% Exit −0.25% 70,000 $1.9M History

0 current, 1 exited last period, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by RIGL's executives, directors and 10% owners in the last 12 months, from their Form 4s

All RIGL insider trades
  • None no insider bought on the open market
  • $145K sold by 1 insider outside a trading plan
  • $73K sold by 1 insider under 10b5-1 plans
  1. Kamil Ali-Jackson Director
    Planned sale
    $73K 2,500 shares at $29.17 17% of stake
    Traded May 26 Filed May 28
    ↗
  2. Walter H Moos Director
    Sale
    $145K 4,000 shares at $36.36 24% of stake
    Traded Feb 20 Filed Feb 24
    ↗

Also filed in the last 12 months, not counted as buying or selling: 20 share withholdings for taxes, 13 stock grants, 12 option exercises, and 1 sale to cover taxes.

SEC filings

Recent issuer filings from EDGAR, 16 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 5.02 Filing Doc
8-K 2.01 Filing Doc
8-K 5.02,5.07 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 1.01 Filing Doc
SCHEDULE 13G — Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 1.02 Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
SCHEDULE 13G/A — Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $116.88M $179.28M $294.28M
Gross profit * $109.77M $160.63M $274.66M
Gross margin * 93.9% 89.6% 93.3%
Net income -$25.09M $17.48M $367.02M
Net margin * -21.5% 9.8% 124.7%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $99.27M $135.1M $240.17M
Total non-current assets * $17.96M $28.87M $273.43M
Total assets $117.22M $163.98M $513.59M
Total current liabilities $53.27M $63.3M $99.24M
Total non-current liabilities * $92.6M $97.39M $22.88M
Total equity -$28.64M $3.29M $391.48M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$5.74M $31.47M $75.66M
Cash from investing -$4.3M $4.13M -$92.36M
Cash from financing $18.37M -$11.64M $0.601M
Net change in cash * $8.33M $23.96M -$16.11M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.